A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes. Our innovative CNS portfolio is anchored by three U.S. Food and Drug Administration (FDA) approved commercial products: AUVELITY® for the treatment of major depressive disorder (MDD), SUNOSI® for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO® for the acute treatment of migraine with or without aura in adults. Total revenues from our three commercial products totaled $638.5 million for 2025, representing 66% annual growth compared to 2024.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 638M | 638M | 386M | 271M | - | - |
| Net Income | -183M | -183M | -287M | -239M | -187M | -130M |
| EPS | $-3.68 | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 |
| Free Cash Flow | -94M | -94M | -129M | -146M | -117M | -109M |
| ROIC | -282.0% | -82.6% | -120.8% | -64.8% | -91.8% | -112.2% |
| Gross Margin | 92.6% | 92.6% | 91.4% | 78.6% | - | - |
| Debt/Equity | 3.19 | 3.19 | 3.33 | 0.98 | 0.86 | 3.14 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -167M | -167M | -281M | -232M | -180M | -125M |
| Operating Margin | -26.1% | -26.1% | -72.7% | -85.7% | - | - |
| ROE | -207.5% | -252.1% | -503.8% | -125.3% | -170.8% | -201.5% |
| Shares Outstanding | 50M | 50M | 48M | 45M | 41M | 38M |
| Metric | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | 271M | 386M | 638M | 638M |
| Gross Margin | N/A | N/A | 78.6% | 91.4% | 92.6% | 92.6% |
| R&D | 58M | 58M | 98M | 187M | 183M | 183M |
| SG&A | 67M | 159M | 323M | 411M | 571M | 571M |
| EBIT | -125M | -180M | -232M | -281M | -167M | -167M |
| Op. Margin | N/A | N/A | -85.7% | -72.7% | -26.1% | -26.1% |
| Net Income | -130M | -187M | -239M | -287M | -183M | -183M |
| Net Margin | N/A | N/A | -88.4% | -74.5% | -28.7% | -28.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -112.2% | -91.8% | -64.8% | -120.8% | -82.6% | N/M |
| ROE | -201.5% | -170.8% | -125.3% | -503.8% | -252.1% | -207.5% |
| ROA | -95.2% | -56.5% | -40.7% | -50.5% | -29.1% | -26.6% |
| Cash Flow | ||||||
| Op. Cash Flow | -108M | -117M | -145M | -128M | -93M | -93M |
| Free Cash Flow | -109M | -117M | -146M | -129M | -94M | -94M |
| Owner Earnings | -129M | -159M | -215M | -221M | -194M | -194M |
| CapEx | 308K | 702K | 582K | 270K | 480K | 480K |
| Maint. CapEx | 76K | 4.4M | 6.8M | 6.9M | 6.9M | 6.9M |
| Growth CapEx | 232K | 0 | 0 | 0 | 0 | 0 |
| D&A | 76K | 4.4M | 6.8M | 6.9M | 6.9M | 6.9M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 21M | 38M | 63M | 85M | 94M | 94M |
| Debt Repayment | 309K | 22M | 1.4M | 0 | 332M | 332M |
| Balance Sheet | ||||||
| Net Debt | -37M | -307M | -586M | -441M | -365M | -42M |
| Cash & Equiv. | 86M | 201M | 386M | 315M | 323M | 323M |
| Long-Term Debt | 49M | 94M | 178M | 181M | 118M | 118M |
| Debt/Equity | 3.14 | 0.86 | 0.98 | 3.33 | 3.19 | 3.19 |
| Interest Coverage | -27.0 | -23.4 | -13.9 | -14.2 | -16.1 | -16.1 |
| Equity | 16M | 110M | 191M | 57M | 88M | 88M |
| Total Assets | 88M | 331M | 588M | 568M | 690M | 690M |
| Total Liabilities | 72M | 222M | 397M | 511M | 602M | 602M |
| Intangibles | N/A | 60M | 53M | 47M | 41M | 41M |
| Retained Earnings | -409M | -596M | -836M | -1.1B | -1.3B | -1.3B |
| Working Capital | 63M | 149M | 365M | 255M | 210M | 210M |
| Current Assets | 87M | 246M | 504M | 485M | 589M | 589M |
| Current Liabilities | 23M | 97M | 139M | 230M | 379M | 379M |
| Per Share Data | ||||||
| EPS | -3.47 | -4.60 | -5.27 | -5.99 | -3.68 | -3.68 |
| Owner EPS | -3.44 | -3.90 | -4.73 | -4.60 | -3.90 | -3.90 |
| Book Value | 0.42 | 2.69 | 4.21 | 1.19 | 1.77 | 1.77 |
| Cash Flow/Share | -2.88 | -2.86 | -3.20 | -2.68 | -1.88 | -3.54 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 37.6M | 40.7M | 45.4M | 47.9M | 49.8M | 49.8M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -50.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 89.0 | 27.8 | 18.9 | 72.9 | 85.7 | 103.8 |
| Price/Sales | N/A | N/A | 11.8 | 10.5 | 9.2 | 14.4 |
| FCF Yield | -7.8% | -3.8% | -4.0% | -3.1% | -1.2% | -1.0% |
| Market Cap | 1.4B | 3.1B | 3.6B | 4.2B | 7.6B | 9.2B |
| Avg. Price | 51.94 | 42.85 | 70.31 | 84.33 | 117.40 | 184.18 |
| Year-End Price | 37.02 | 75.00 | 79.62 | 86.70 | 152.05 | 184.18 |
Axsome Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 87.5%.
Axsome Therapeutics, Inc. (AXSM) has a 5-year average return on invested capital (ROIC) of -94.4%. This is below average and may indicate limited pricing power.
Axsome Therapeutics, Inc. (AXSM) has a market capitalization of $9.2B. It is classified as a mid-cap stock.
Axsome Therapeutics, Inc. (AXSM) does not currently pay a regular dividend.
Axsome Therapeutics, Inc. (AXSM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Axsome Therapeutics, Inc. (AXSM) reported annual revenue of $638 million in its most recent fiscal year, based on SEC EDGAR filings.
Axsome Therapeutics, Inc. (AXSM) has a net profit margin of -28.7%. The company is currently unprofitable.
Axsome Therapeutics, Inc. (AXSM) generated $-94 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Axsome Therapeutics, Inc. (AXSM) has a debt-to-equity ratio of 3.19. This indicates higher leverage, which may increase financial risk.
Axsome Therapeutics, Inc. (AXSM) reported earnings per share (EPS) of $-3.68 in its most recent fiscal year.
Axsome Therapeutics, Inc. (AXSM) has a return on equity (ROE) of -252.1%. A negative ROE may indicate losses or negative equity.
Axsome Therapeutics, Inc. (AXSM) has a 5-year average gross margin of 87.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for Axsome Therapeutics, Inc. (AXSM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Axsome Therapeutics, Inc. (AXSM) has a book value per share of $1.77, based on its most recent annual SEC filing.